NanoBio Corp., an Ann Arbor, Mich.-based developer of anti-infective products and mucosal vaccines, has raised $10 million in new equity funding from Perseus LLC. This is the third and final tranche of a $30 million round, and was triggered by the completion of certain clinical milestones.
NanoBio
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.